Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes

Incidence rate of severe hypoglycemia,Incidence rate of DKA,A1c at 3, 6, 9 and 12 months,Percentage of time 54 mg/dL,Percentage of time 70 mg/dL,Percentage of time 180 mg/dL,Percentage of time 250 mg/dL,Percentage of time in range 70-180 mg/dL,Mean Glucose mg/dL,Standard deviation of glucose mg/dL,Glucose management indicator %,Percentage of participants achieving A1C 7%,Percentage of participants with time in range 70%,Percentage of participants with time below range (70mg/dL) of 4%,Insulin Usage,Body Mass Index (BMI) or BMI z-score,EQ-5D (inclusive of the Visual Analogue Scale (VAS)),Insulin Delivery Systems: Perceptions, Ideas, Reflections, and Expectations (INSPIRE),System Usability Scale (SUS),Incidence rate of prolonged hyperglycemia (events per person months) during usage of Activity Feature,Incidence rate of prolonged hyperglycemia (events per person months),Incidence rate of prolonged hyperglycemia (events per person months) during usage of a Target Glucose of 140 mg/dL or 150 mg/dL,Glucose Outcomes during the 4-hour post-bolus period using the SmartBolus Calculator: o Percentage of time 54 mg/dL o Percentage of time in range 70-180 mg/dL

This is a decentralized observational clinical registry to collect real-world evidence
 related to the safety and effectiveness of the Omnipod 5 system in children and adults with
 Type 1 Diabetes.